TURALIO
Drug timelines are a Plus or Pro feature.
17 regulatory and trial events tracked for TURALIO, covering 2017-05-03 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... [Phase 1]